Key result
Deriving endothelial cells de novo from human pluripotent stem cells provides an unprecedented opportunity to discover novel drug targets, revascularize ischemic tissues, and engineer tissue constructs.
Answers are grounded in this paper and cite their sources.
Endothelial cells (ECs) are critical for several aspects of cardiovascular disease therapy, including vascular regeneration, personalized drug development, and tissue engineering. Human pluripotent stem cells (hPSCs) afford us with an unprecedented opportunity to produce virtually unlimited quantities of human ECs. In this review, we highlight key developments and outstanding challenges in our ability to derive ECs de novo from hPSCs. Furthermore, we consider strategies for recapitulating the vessel- and tissue-specific functional heterogeneity of ECs in vitro. Finally, we discuss ongoing attempts to utilize hPSC-derived ECs and their progenitors for various therapeutic applications. Continued progress in generating hPSC-derived ECs will profoundly enhance our ability to discover novel drug targets, revascularize ischemic tissues, and engineer clinically relevant tissue constructs. Visual Overview- An online visual overview is available for this article.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2019) conducted a review in Cardiovascular disease. Human pluripotent stem cell-derived endothelial cells was evaluated. Deriving endothelial cells de novo from human pluripotent stem cells provides an unprecedented opportunity to discover novel drug targets, revascularize ischemic tissues, and engineer tissue constructs.
Synapse has enriched 10 related papers. Consider them for comparative context: